Market Cap (In CAD)
9.92 Million
Revenue (In CAD)
-
Net Income (In CAD)
-3.61 Million
Avg. Volume
46.93 Thousand
- Currency
- CAD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.04-0.1
- PE
- -0.88
- EPS
- -0.04
- Beta Value
- 0.825
- ISIN
- CA76128M1086
- CUSIP
- 76128M108
- CIK
- -
- Shares
- 283497000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Donald J. McCaffrey
- Employee Count
- -
- Website
- https://www.resverlogix.com
- Ipo Date
- 2004-05-07
- Details
- Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
More Stocks
-
6563Mirai Works Inc.
6563
-
RMDResMed Inc.
RMD
-
TBVPF
-
002428
-
CIENCiena Corporation
CIEN
-
FCR-UN
-
GICRE
-
SPIRSpire Global, Inc.
SPIR